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Summary The role of cyclic adenosine monophosphate/protein kinase A (cAMP/PKA) signaling in
the molecular pathways involved in fear and memory is well established. Prior studies in our lab
reported that transgenic mice with an inactivating mutation in Prkar1a gene (codes for the 1-alpha
regulatory subunit (R1a) of PKA) exhibited behavioral abnormalities including anxiety and depres-
sion. In the present study, we examined the role of altered PKA signaling on anxiety-like behaviors in
Prkar1a+/mice compared to wild-type (WT) littermates. The elevated plus maze (EPM) and marble
bury (MB) tests were used to assess anxiety-like behavior. The hotplate test was performed to
evaluate analgesia. We further examined the impact of the Prkar1a inactivating mutation on PKA
activity in specific nuclei of the brain associated with anxiety-like behavior. Results for the MB test
showed a genotype effect, with increased anxiety-like behavior in Prkar1a+/ mice, compared to
WT littermates ( p < 0.05). MANOVA analysis showed a significant genotype difference in anxiety-
like behavior in the EPM between WTand Prkar1a+/mice on combined dependent variables (open
arm time and open to total time ratio; p < 0.05). Results of hotplate testing showed no genotype
effect however; the expected sex difference was noted. Analysis of PKA activity showed the loss of
one Prkar1a allele led to an increase in basal and cAMP-stimulated kinase activity in both the
basolateral and central amygdala. These results suggest that the alteration in PKA signaling in
Prkar1a+/ mice is not a ubiquitous effect; and supports the importance of cAMP/PKA pathway in
neurobiological processes involved in anxiety and fear sensitization.
Published by Elsevier Ltd.
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1. Introduction
The hypothalamic pituitary adrenal (HPA) axis and the auto-
nomic nervous system have been the primary foci of research
to elucidate the neurobiological mechanisms involved in the
stress response. Typically the stress response has been iden-
tified as a ‘‘fight or flight’’ reaction, but may also include an
increased state of vigilance, which is often accompanied by
increased anxiety. Prolonged or repeated exposure to stress
often results in physiological, psychological, and behavioral
morbidities (i.e. anxiety, depression, post-traumatic stress
disorder) in animals and humans. Anxiety is a normal
response to a potentially threatening situation, which serves
a physiological protective function. However, behavioral
flexibility is advantageous in many situations, and this ability
may be impaired in anxiety disorders (Schiller et al., 2008).
Anxiety is considered pathological when there is a bias to
interpret ambiguous situations as threatening, with beha-
vioral responses of avoidance or exaggerated reactions to
potential threats (Wood and Toth, 2001).
There is ample evidence to support the role of various
neurotransmitters systems in the pathophysiology of anxiety
and stress-activated behaviors (y-aminobutyric acid, seroto-
nin, epinephrine, dopamine, corticotrophin-releasing factor,
cholecystokinin, and neuropeptide Y), and pharmacological
agents are targeted to these systems to treat anxiety dis-
orders. Recently, transgenic mice with an anxiety-like phe-
notype were developed by targeted inactivation of genes
associated with either chemical or neuronal signaling
between neurons. This work has identified two groups of
anxiety-relevant molecules, one that is involved with neu-
ronal development and cell-to-cell communication (neuro-
trophic-type molecule) and the other with the regulation of
intracellular signaling and gene expression (Wood and Toth,
2001). Research using mice with targeted inactivation of
genes related to these molecules are valuable tools to pro-
vide insight regarding how abnormal development and/or
function of neuronal networks affect the manifestation of
anxiety disorders.
The role of cAMP/PKA signaling in molecular pathways
involved in fear and fear memory is well established. PKA is a
naturally occurred holoenzyme known to have a critical role
in anxiety and formation of fear memories. PKA is a four-
membered structure with two regulatory (R) and two cata-
lytic (C) subunits. The R subunit isoforms exhibit major
differences in the tissue distribution, biochemical and phy-
sical properties encoded by four genes (RI-Alpha, RI-Beta, RII-
Alpha and RII-Beta) (Tasken et al., 1993). Several research
groups have reported CNS effects in knock-out models for RI-
Beta (Brandon et al., 1995, Huang et al., 1995), RII-Alpha
(Rao et al., 2004) and RII-Beta (Brandon et al., 1998), as well
as catalytic unit knockouts (Huang et al., 1995; Qi et al.,
1996; Howe et al., 2002). RI-Alpha (R1a/), RII-Alpha(RIIa/
), & R1-Beta (R1B/), — subunit deficient mice were shown
to have reduced cAMP — stimulated (and PKI-inhibited) PKA
activity, while only the RI-Alpha (R1a/) mice showed sig-
nificantly increased baseline (non cAMP-stimulated, but PKI
inhibited) PKA activity. The absence of a severe phenotype in
RII-Alpha, RII-Beta and R1-Beta, but not in RI-Alpha (R1a/)
deficient mice supports the essential role of the R1-Alpha
regulatory subunit on maintaining the catalytic subunit under
cAMP control. (Adams et al., 1997; Planas et al., 1999;
Cummings et al., 1996; Schreyer et al., 2001; Brandon et
al., 1998; Amieux et al., 1997; Burton et al., 1997, 1999).
Studies with Gsalpha transgenic mice have shown that
increased cAMP signaling is associated with an anxiety-like
phenotype (Favilla et al., 2008). Zhang et al. (2008) recently
reported that mice with reduced phosphodiesterase 4B activ-
ity, the enzyme that degrades cAMP and interrupts the
negative feedback of PKA pathway resulting in increased
PKA activity, displayed anxiogenic behavior. In addition,
transgenic mice with overexpression of the striatially
enriched cAMP-producing adenyl cyclase 5, showed increased
anxiety-related behavior (Kim et al., 2008). Results of the
studies reviewed above indicate that increased cAMP signal-
ing is associated with an anxiety-like phenotype, and provide
indirect evidence that an increase in PKA activity may be
associated with an increased risk for anxiety.
Prior studies in our lab showed that transgenic mice with a
down-regulated Prkar1a gene (tTA/X2AS, antisense trans-
gene, codes for the 1-alpha regulatory subunit (R1a) of
PKA) (Griffin et al., 2004a) exhibited behavioral abnormal-
ities, including anxiety (Batista et al., 2005) and depression.
A knockout mouse heterozygous for a null allele of Prkar1a
was recently developed in our lab as a model to investigate
Carney complex (Kirschner et al., 2005). Carney complex is
an autosomal dominant multiple neoplasia syndrome that is
associated with inactivating mutations of the PRKAR1A gene,
resulting in a net increase in PKA activity.
The null allele functionally results in increased PKA signal-
ing. It is likely that disease-related symptoms are related to
long term changes in neuronal function, therefore a transgenic
mouse model with down-regulation of Prkar1a provides a
research tool to test for the first time the effect of altered
PKA expression on anxiety-like behavior. The objective of this
study was to examine the role of altered PKA signaling on
anxiety-like behaviors using behavioral assays known to be
sensitive to anxiolytics in Prkar1a mice (HZ) compared to wild-
type (WT) littermates. In addition, we measured the expres-
sion in PKA activity (basal and cAMP stimulated) in various
brain areas in Prkar1a+/ mice and WT control littermates to
evaluate possible associations of altered PKA activity with the
behavioral phenotype. The inclusion of a nocioceptive assess-
ment is important to in the behavioral phenotype of the
Prkar1a knock-out mouse since the amygdala is known to have
a key role in the emotional—affective dimension of pain as well
as anxiety behavior.
2. Methods
2.1. Animals
All mice were housed three to four per cage with same-sex
littermates with ad libitum access to food and water and
maintained on a 12:12 light schedule (lights on at 0600 h). All
animals were adults at the time of testing (2—10 months old).
Throughout the entire experimental period, the mice were
handled and weighed to acclimate to the investigator. All
animal procedures were conducted in accordance with the
standards approved by the NIH Guide for the Care and Use of
Laboratory Animals. All animal protocols received prior
approved at the NIH.
Prkar1a+/ mice (which contain one null allele of
Prkar1aD2) were previously generated in our laboratory
+ Models
PNEC-2065; No. of Pages 8
Please cite this article in press as: Keil, M.F., et al., Anxiety phenotype in mice that overexpress protein kinase A. Psychoneuroendocrinology
(2011), doi:10.1016/j.psyneuen.2011.09.016
2 M.F. Keil et al.
(Kirschner et al., 2005). R1a haploinsufficiency leads to
increased total PKA activity in response to cAMP in addition
to increased PKA-II to PKA-1 ratio (Griffin et al., 2004a,b;
Amieux et al., 1997; Robinson-White et al., 2006). All mice
were bred into a mixed C57BL/6 129Sv/B6 hybrid background
to generate Prkar1a+/ and control (wild type, WT) mice
were used from the same litters. Adrenal tumor or cortisol
overproduction was not identified in Prkar1a knock-out mice.
Genotype-specific cardiac and adrenal lesions were not seen
in Prkar1a+/ mice; however, benign and malignant thyroid
neoplasias were observed in some older mice (Kirschner
et al., 2005). Standard assessment of neurological function
revealed no deficits in Prkar1a+/mice. It was not uncommon
for Prkar1a+/ mice to develop nonpigmented schwannomas
and fibro-osseous bone lesions beginning at approximately 6
months of age; however, no other physical abnormalities
were noted. A few transgenic mice that were used in this
study had early tail tumors; however, none of the mice used
in this study had evidence of thyroid or other tumors.
Heterozygous (Prkar1a+/) and wild-type (WT) males and
females were tested with various behavioral assays in order
to characterize the phenotype of Prkar1a+/ mice. All beha-
vioral testing was performed between the hours of 1300—
1700 h. One behavioral test per day was performed, with a
span of at least 2 days between tests. The order of behavioral
tests performed was randomly distributed, since confounding
effects have not been reported for EPM, marble bury, and
hotplate tests (Espejo, 1997a). Two scorers performed beha-
vioral testing and scoring of results in a blinded fashion.
2.2. Genotyping analysis
Initial genotyping of founders was by polymerase chain reac-
tion (PCR of tail DNA) that was then used to genotype our mice
containing one null allele (Prkar1aD2) and those with the NEO
cassette within prkar1a gene: three primers (50-AGC-
TAGCTTGGCTGGACGTA-30, 50-AAGCAGGCGAGCTATTAGTTTAT-
30 and 50-CATCCATCTCCTATCCCCTTT-30) were used for prkar1a
genotyping: the WTallele generated a 250 bp fragment and the
null allele generated an 180 bp product (Kirschner et al.,
2005).
2.3. Measurement of anxiogenic-like behavior
Marble bury test was performed as previously described (Treit
et al., 1981; Njung‘e and Handley, 1991; Broekkamp et al.,
1986). Mice were transported in their home cages to the
testing room 2 h prior to acclimate to the room prior to the
experiment. Standard rodent sawdust bedding was placed in
standard mouse cages (38 cm  22 cm  16 cm) and eight
dark colored marbles were placed on top of the bedding in
two evenly spaced rows and the cage was closed with stan-
dard lid. No food or water was present during the 30-min test
period. Lights were turned off in the room and after 30-min
the number of marbles buried (>2/3 marble covered by
bedding material) was recorded.
Elevated plus maze (EPM) testing was performed as
described previously (Pellow et al., 1985; Lister, 1987). Mice
were transported in their home cages to the testing room 2 h
prior to acclimate prior to testing. The EPM consists of two open
arms (30 cm  5 cm) and two enclosed arms (30 cm  5 cm),
with end and side-walls (15 cm height), and a center platform
(5 cm  5 cm). The maze was raised to a height of 38 cm above
the counter and illuminated (100 lux) from above. The mouse
was placed in the center area of the EPM, facing an open arm,
and allowed to explore the maze for 5 min. Tests were video
recorded and analyzed by ANY-maze software# (Stoelting Co.,
Wood Dale, IL, USA). Arm entry was defined as all four paws in
an arm or center area. After 5 min, the mouse was removed
from the EPM, the number of boli recorded, the maze cleaned
with 70% ethanol and allowed to dry prior to testing the next
mouse. In addition, hand scoring was performed to validate
time and entries into arms, as well as record risk assessment
behavior (calculated by dividing number of protected stretch
attend postures by total closed arm time) and exploratory
behavior (head dips). Measures scored included: open and
closed arm time, open and closed arm entries, open to total
time ratio (open arm time/open arm time + closed arm time),
number of head dips, and number of protected stretch attend
postures (defined as two hind feet remaining in closed arm
while the mouse elongated its head and shoulders, followed by
retraction), and risk assessment ratio (number of protected
stretch attend postures/amount of closed arm time). Time
spent in center area of the maze was not counted (Weiser et al.,
2009).
The number of closed arm entries is used as a measure of
locomotor activity. A video recording device and automated
scoring software (ANY-MAZE#) allow standardization and
objectivity for behavior in the EPM.
2.4. Measurement of nocioception
This test was performed as described previously (Ballou
et al., 2000). Mice were transported in their home cages
to the testing room 1—2 h prior to acclimate to the room
change prior to testing. The mouse was placed on a hotplate
inside a clear plastic cylinder, with the temperature of the
hotplate set to 50 8C. Latency to lick the hind-paw was
recorded. If no response was observed after 45 s, the mouse
was removed from the hotplate, to avoid any tissue injury.
2.5. PKA assay
Prkar1a+/ and WT littermates were moved to testing room
2 h prior to euthanization by CO2. The brains were removed
and immediately frozen (80 8C) until cyrosectioning. Cyro-
sections of 250 mm and punch biopsies (0.5 mm diameter
stainless steel punch) of tissue from the following brain
regions were obtained using the punch method of Palkovits
(1983): central and basolateral amygdala, ventromedial
hypothalamus, paraventricular hypothalamus, thalamus,
and orbitofrontal cortex. Olfactory bulb, eyes, and cerebel-
lum were dissected in entirety and stored in cyrotubes at 80
prior to homogenization and measurement of PKA activity.
The mouse brain atlas of Paxinos and Franklin (2001) was used
to guide the dissections.
PKA enzymatic activity was measured following the proto-
col described earlier by Nesterova et al. (1975, 2008). The
assays were carried out in a total volume of 50 mL for 15 min at
37 8C in the reaction mixture containing 1 mol/L Tris—HCl (pH
7.5), 1 mol/L DTT, 1 mol/L MgCl2, 60 mmol/L Kemptide (a
phosphate acceptor peptide; Leu-Arg-Arg-Ala-Ser-Leu-Gly),
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20 mmol/L [g-32P] ATP (25 Ci/mmol), with or without 5 mmol/
L cAMP and 10 mL of the cell extracts. After incubation, the
reaction mixtures were spotted onto 0.23-mm phosphocellu-
lose discs and washed thrice in 0.5% phosphoric acid. Filters
were air dried and counted by liquid scintillation counter. Basal
levels of PKA activity represent the non-stimulated PKA activ-
ity. Total PKA activity reflects the PKA activity after the
addition of cAMP. PKA values were normalized by protein
content of each sample.
2.6. Statistical analysis
Data were analyzed for effect of genotype and sex by ANOVA
and Bonferroni post hoc comparisons where appropriate
using SPSS statistical software. Significance was determined
at p < 0.05. All values are reported as means  SEM. Beha-
vioral measures in the EPM were analyzed by a multifactorial
ANOVA, with between subjects’ factors of sex and genotype.
3. Results
3.1. Measurement of anxiogenic-like behavior
To differentiate sex and/or genotype effect on anxiety-like
behavior on novelty induced locomotor activity, the marble
bury test was performed. Prkar1a+/(males and females)
mice were compared to WT (males and females) littermates.
ANOVA analysis showed a significant difference, with
increased marble burying for Prkar1a+/ compared to WT
mice In addition, an interaction between sex and genotype
was noted, with Prkar1a+/females burying more marbles
than all other groups (F = 4.345; p < 0.05) (WT vs. Prkar1a+/
males: 4.3  0.5 vs. 5.9  0.4; WT vs. Prkar1a+/ females:
5.2  0.5 vs. 6.5  0.4; n = 19—26 per group) (Fig. 1).
To examine sex differences and the impact of the null
mutation on anxiety behaviors the EPM, a test of uncondi-
tioned response to novelty, was performed. A one-way
between groups multivariate analysis was performed to
investigate genotype differences in anxiety-like behavior
in the EPM. Four dependent variables, open arm time, open
to total arm time ratio, risk assessment, and total head dips
were used. A significant difference was noted between WT
and Prkar1a+/ mice on the combined dependent variables
(F 2.892), p = 0.03, Wilks’ lambda = 0.874; partial eta
squared = 0.126). There was a significant difference between
WT and Prkar1a+/ mice for open arm time (WT 24.1  3.9 s,
vs. Prkar1a+/ 10.1  4.2; p < 0.05) (Fig. 2a) and open to
total arm ratio (WT 0.1  0.02 vs. Prkar1a+/ 0.04  0.02;
p < 0.05) (Fig. 2b). However, no genotype or gender effect
was found for risk assessment behavior (WT 0.05  0.004 vs.
Prkar1a+/ 0.05  0.005) or total head dips (WT 6.9  0.7 vs.
Prkar1a+/ 6.2  0.7) (n = 37—50 per group). The number of
closed arm entries was used as an indicator of locomotor
activity and no genotype or gender differences were found
(Males: WT 8  0.7, Prkar1a+/ 7.6  1; females: WT 7  0.8,
Prkar1a+/ 8.4  0.9). These results indicate that locomotion
did not influence the measures of anxiety-like behavior.
3.2. Measurement of nocioception
To investigate the potential role of Prkar1a in nocioception we
examined the response in the hot-plate test. ANOVA analysis of
latency to lick response in the hotplate test showed the
expected sex differences, with a longer latency in females
compared to males (males: WT 28.8  1.6, Prkar1a+/
23.6  1.8 s vs. females: WT 32.6  1.9, Prkar1a+/
32.6  1.7 s; p < 0.05; n = 15—22 per group). No genotype
effect was found. This suggests that the alteration in PKA
signaling is not a ubiquitous effect, similar to what has been
described in the Prkar1a mouse model, and provides an
important positive control for this study.
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Figure 1 Marble Bury Test. Mean (SEM) number of marbles
buried 2/3 or greater after 30 min. Prkar1a+/ mice buried
significantly more marbles than WT littermates (*p < 0).
Figure 2 (a) Elevated plus maze: open arm time. Mean (SEM)
time in seconds of time mouse spent in open arm of elevated plus
maze test (total test time 5 min.) Prkar1a+/ mice spent signifi-
cantly less time in open arm than WT littermates (*p < 0.05). (b)
Elevated plus maze: ratio of open arm time to total time. Mean
(SEM) percentage of time that mouse spent in open arm of
elevated plus maze test (i.e. open arm time/(open arm + closed
arm time). Prkar1a+/mice had significantly lower percentage of
open to total time than WT littermates (*p < 0.05).
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3.3. PKA activity
To investigate possible anatomical sites associated with
changes in anxiety-like behavior we studied PKA activity in
the brain of WT and Prkar1a+/ mice. ANOVA analysis showed
no differences in PKA activity between male and female mice
and no relation to age so all data were pooled together for
analysis. In a control (non-stressed) situation the loss of one
Prkar1a allele led to an increase in basal kinase activity in both
the basolateral (WT 2867  518 vs. Prkar1a+/ 12124 
3841  cAMP/1 mcg, p < 0.03) and central amygdala (WT
3196  693 vs. Prkar1a+/ 10923  3097  cAMP/1 mcg,
p < 0.05) (Fig. 3a) and cAMP-stimulated kinase activity (WT
16717  2938 vs. Prkar1a+/ 510230  14301 + cAMP/1 mcg,
p < 0.03; WT 21448.1  6380 vs. Prkar1a+/ 68329 
16916 + cAMP/1 mcg; basolateral and central amygdala
respectively, p < 0.02) (Fig. 3b) compared to the WT mice
(n = 13—14 per group). The thalamus exhibited the highest
basal and total PKA activity among WT mice, whereas
the paraventricular hypothalamus and orbitofrontal cortex
PKA activity did not parallel the increased activity of
basolateral and central amygdala in the Prkar1a+/ group
(Fig. 3a and b). No differences in basal or stimulated (cAMP-
stimulated kinase) activity were found between WT and
Prkar1a+/mice in: ventromedial hypothalamus, cerebellum,
olfactory bulb, or eyes (data not shown). In both genotypes,
however, basal and cAMP-stimulated kinase differed signifi-
cantly ( p < 0.05) in all studied brain areas.
4. Discussion
4.1. Behavioral responses to novel stressors
The present findings demonstrate that mice with a down-
regulation of the regulatory subunit of PKA, exhibit beha-
vioral changes in tests that measure anxiety (EPM and
marble) suggesting a key role of PKA in modulating anxi-
ety-related behaviors. Compared to WT mice, Prkar1a+/
mice had higher basal and stimulated (cAMP) PKA activity
levels in the central and basolateral amygdala, brain areas
known to have a critical role in the processing of sensory
information related to anxiety and emotion as well as reg-
ulation of arousal level. The EPM relies on the innate motiva-
tional conflict between the drive to explore a novel
environment (approach behavior) in opposition to the fear
of open space (avoidance behavior). Anxiolytic compounds
increase the proportion of open arm exploration relative to
total arm exploration, whereas anxiogenic compounds
reduce open arm exploration (spatiotemporal measures)
(Lapiz-Bluhm et al., 2008). In this study Prkar1a+/ mice
displayed a decrease in the number of entries into the open
arms of the maze as well as an increase in the amount of time
spent in the closed arms (spatiotemporal measures) when
compared to WT littermates. Consistent with the findings of
the EPM, results of the marble bury test, another test of
novelty that involves approach-avoidance behavior, also
showed a genotype effect. These findings suggest that the
observed behavior of Prkar1a+/ mice relates to ‘‘trait’’
rather than ‘‘state’’ anxiety, since these tests discriminate
between approach and avoidance responses to novel envir-
onments.
In contrast with the results of the spatiotemporal mea-
sures of the EPM, it is interesting that no genotype difference
was found in risk assessment or exploratory behaviors in the
EPM, which implies that arousal behavior was similar
between the two groups. Recent studies report that risk
assessment behavior is a highly sensitive index of anxiety,
based on ethological and pharmacological manipulations
(Carobrez and Bertoglio, 2005; Espejo, 1997b; Cole et al.,
1995), while head dipping is as an index of exploratory
behavior (head dip over side arm of the maze) (Rogers and
Johnson, 1995). Factor analysis studies support the segrega-
tion of behavioral and neural mechanisms controlling risk
assessment and open arm exploration in the EPM (Adamec
et al., 1999, 2001). In our study, although exposure to the
open arm area functioned as a stressor that was sufficient to
elicit increased anxiety-like (avoidance) behavior Prkar1a+/
mice, the similarities in risk assessment and exploratory
behaviors of WT and Prkar1a+/ suggest that alteration in
PKA activity discriminated between anxiogenesis and seda-
tion. Importantly, these behaviors were observed in the
absence of changes to total arm entries, suggesting that
the observed changes in spatiotemporal-related measures
+ Models
PNEC-2065; No. of Pages 8
Please cite this article in press as: Keil, M.F., et al., Anxiety phenotype in mice that overexpress protein kinase A. Psychoneuroendocrinology
(2011), doi:10.1016/j.psyneuen.2011.09.016
Figure 3 (a and b) Means (SEM) of: (a) basal and (b) cAMP-
stimulated PKA activity between wild type mice and mice with
loss of one Prkar1a allele in a control (non-stressed) situation in
basolateral and central amygdala, paraventricular hypothala-
mus, thalamus, and orbitofrontal cortex. Significantly increased
basal and total PKA activity was found in basolateral and central
amygdala in Prkar1a+/ mice compared to WT littermates
(*p < 0.05).
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in the EPM were behaviorally selective. The finding of low
open arm time, but no difference in risk assessment behavior
of Prkar1a+/mice support findings of prior studies that note
differences in the anxiety pathways related to spatiotem-
poral and risk assessment measures of EPM.
Using c-Fos immunocytochemistry to map neural circuits
underlying behavioral responses, various studies have
reported that the prefrontal cortex and amygdala are the
main brain areas activated after exposure to the EPM (Rubino
et al., 2007; Hinks et al., 1996). Results of our study showed
no difference in baseline PKA activity in the prefrontal
cortex, an area known to have extensive reciprocal connec-
tions with the amygdala, which suggests that the alteration
of PKA activity noted in the amygdala of HZ mice may play a
role in the inhibition of approach in situations of fear and
promotes risk assessment behavior at the expense of flight.
Mcnaughton and Corr (2004) proposed a two-dimensional
hierarchal view of defensive behavior that provides a clear
distinction between fear and anxiety. Fear functions to move
the animal away from danger (defense avoidance system),
the neural control is more elaborated at lower levels of the
neural system, and is insensitive to anxiolytics. Anxiety
functions to move the animal toward danger (defensive
approach system), the neural control is more elaborated
at higher levels of the neural system, and is sensitive to
anxiolytics. In addition, anxiety involves inhibitory behavior
and increased risk assessment (vigilance). The discrepancy
noted between the increased anxiety-like behavior noted in
spatiotemporal measures in the EPM and marble bury test,
with no difference in risk assessment behavior, suggests that
alterations in PKA activity independently affect neural path-
ways associated with various aspects of anxiety behavior.
Data presented here suggest that the effect of down reg-
ulation of the regulatory subunit of PKA is localized to the
amygdala, since Prkar1a+/ mice showed increased anxiety-
like behaviors and increased PKA activity in the amygdala, but
not in the cortex. The role of the amygdala in the control of
fear and anxiety is well established. Studies of anxiolytic
compounds show that these agents act to reduce the arousal
associated with anxiety, and that the intensity of amygdala
activation is equated with arousal level, which is not mediated
by the septo-hippocampal system (Mcnish et al., 1997; Davis,
2000, 1992). This does not rule out the possibility that
increased PKA activity is not acting elsewhere in the brain
(i.e. paraventricular hypothalamus, ventromedial hypothala-
mus, or other brain areas involved with neural pathways of
anxiety) through compensatory mechanisms; but an amygdala
localized effect is consistent with extensive data on the role of
the amygdala in anxiety and fear-related behaviors.
4.2. Behavioral response to nocioceptive stimuli
An assessment of response to nocieceptive stimuli is relevant
in the behavioral phenotype of the Prkar1a+/ mouse since
the amygdala has a key role in both the emotional—affective
processing of pain and anxiety behavior. Specifically the
central nucleus of the amygdala receives nocioceptive infor-
mation directly from the spinal cord and brainstem, and
indirectly through the basolateral amygdala, thalamus,
and cortex. The amygdala is important in nociofensive
behavior as well as for pain inhibition. There is a paucity
of data regarding the conditions that result in a pro- or
anti-nocioceptive amygdala response and the molecular
mechanisms involved. Little is known about the pain-related
functions and interactions of various protein kinases, includ-
ing PKA, PKC, and ERK in the amygdala (Fu et al., 2008). The
hotplate pawlick test is a well-validated measure of analge-
sia in rodents that measures the spontaneous reaction to
thermal nocioception. Unknown differences may pre-exist in
a transgenic model that may affect pain sensitivity, so a
baseline assessment is important in order to determine
whether alterations in PKA activity affect pain response. In
the present study, it is interesting that although basal and
stimulated PKA activity in the basolateral and central amyg-
dala were increased in HZ compared to WT, no genotype
effect was found for nocioception; however, the expected
sex difference in latency response remained intact.
Data from this study show no difference in basal or total
PKA activity between WT and Prkar1a+/ mice in the ven-
tromedial hypothalamus, cerebellum, olfactory bulb, or
eyes, which suggests that alteration in PKA signaling is not
a ubiquitous effect, similar to what has been described in the
Prkar1a+/mouse model (Tsang et al., 2010; Kirschner et al.,
2005, 2009; Griffin et al., 2004c; Yin et al., 2009). Results
from this study are consistent with prior studies that showed
R1b mice had reduced injury-induced inflammation and pain,
without apparent differences in PKA brain activity, likely due
to compensatory increases in levels of Prkar1a protein (Bran-
don et al., 1995; Amieux et al., 1997; Huang et al., 1995;
Malmberg et al., 1997). This provides an important positive
control for the noted behavioral differences noted between
WT and HZ, which are also mediated by the amygdala. This
data suggests that downstream targets of PKA may be impor-
tant mediators of the response to thermal nocioception and
related to the pain-related plasticity in the amygdala.
4.3. Implications for neurobiology of anxiety
research
We conclude that alterations in PKA signaling, as those that
have been described in the Prkar1a mouse model, result in
specific neurobiological modifications of behaviors involved
in anxiety and fear sensitization in mice. The cAMP response
element (CRE) is present in many genes (Impey et al., 2004;
Zhang et al., 2005) and functions as a promoter/enhancer
element in many brain areas that responds to environmental
stimuli such as psychological stress (Konradi et al., 1994).
PKA activity is also affected by various neurotransmitter
systems that are involved with alertness, anxiety, emotion
or mood through the actions of G-protein coupled receptors
that regulate adenyl cyclase. Our results suggest that a
chronic increase in PKA activity in the amygdala regulates
the anxiety response, and a better understanding of the
downstream targets of increased PKA activity may identify
novel therapeutic targets to treat anxiety.
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